Literature DB >> 3951539

Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy.

K Kärre, H G Ljunggren, G Piontek, R Kiessling.   

Abstract

Metazoan organisms may discriminate between self and non-self not only by the presence of foreign antigens but also by the absence of normal self markers. Mammalian adaptive immune responses use the first strategy, with the additional requirement that foreign antigens are recognized in the context of self-major histocompatibility complex (MHC) products at the cell surface. Aberrant cells which fail to express MHC products adequately can therefore avoid detection. A more primitive but complementary defence system, eliminating such cells on the basis of absent self-markers, is suggested by a re-interpretation of phenomena associated with metastasis and natural resistance. We now show that murine lymphoma cells selected for loss of H-2 expression are less malignant after low-dose inoculation in syngeneic hosts than are wild-type cells, and that the rejection of such cells is non-adaptive. On the basis of our data, we suggest that natural killer cells are effector cells in a defence system geared to detect the deleted or reduced expression of self-MHC.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3951539     DOI: 10.1038/319675a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  609 in total

1.  Impaired natural killer cell self-education and "missing-self" responses in Ly49-deficient mice.

Authors:  Simon Bélanger; Megan M Tu; Mir Munir Ahmed Rahim; Ahmad B Mahmoud; Rajen Patel; Lee-Hwa Tai; Angela D Troke; Brian T Wilhelm; Josette-Renée Landry; Qinzhang Zhu; Kenneth S Tung; David H Raulet; Andrew P Makrigiannis
Journal:  Blood       Date:  2012-06-01       Impact factor: 22.113

Review 2.  Macrophages as mediators of tumor immunosurveillance.

Authors:  Siddhartha Jaiswal; Mark P Chao; Ravindra Majeti; Irving L Weissman
Journal:  Trends Immunol       Date:  2010-05-07       Impact factor: 16.687

3.  Natural killer cell acceptance of H-2 mismatch bone marrow grafts in transgenic mice expressing HLA-Cw3 specific killer cell inhibitory receptor.

Authors:  A Cambiaggi; C Verthuy; P Naquet; F Romagné; P Ferrier; R Biassoni; A Moretta; L Moretta; E Vivier
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-22       Impact factor: 11.205

Review 4.  Cytotoxic immunological synapses.

Authors:  Michael L Dustin; Eric O Long
Journal:  Immunol Rev       Date:  2010-05       Impact factor: 12.988

5.  Analysis of the association of peptides of optimal length to class I molecules on the surface of cells.

Authors:  K L Rock; L Rothstein; B Benacerraf
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-01       Impact factor: 11.205

Review 6.  Histocompatibility antigens and natural killer susceptibility.

Authors:  J Peña; R Solana
Journal:  Immunol Res       Date:  1992       Impact factor: 2.829

Review 7.  Qa-1, a nonclassical class I histocompatibility molecule with roles in innate and adaptive immunity.

Authors:  Peter E Jensen; Barbara A Sullivan; Lisa M Reed-Loisel; Dominique A Weber
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

8.  Glycolytic requirement for NK cell cytotoxicity and cytomegalovirus control.

Authors:  Annelise Y Mah; Armin Rashidi; Molly P Keppel; Nermina Saucier; Emily K Moore; Joshua B Alinger; Sandeep K Tripathy; Sandeep K Agarwal; Emily K Jeng; Hing C Wong; Jeffrey S Miller; Todd A Fehniger; Emily M Mace; Anthony R French; Megan A Cooper
Journal:  JCI Insight       Date:  2017-12-07

9.  Bone Marrow Cell Rejection, MHC, NK Cells, and Missing Self Recognition: Ain't That Peculiar (with Apologies to Marvin Gaye).

Authors:  David H Raulet
Journal:  J Immunol       Date:  2015-10-01       Impact factor: 5.422

10.  Hierarchy among multiple H-2b-restricted cytotoxic T-lymphocyte epitopes within simian virus 40 T antigen.

Authors:  L M Mylin; R H Bonneau; J D Lippolis; S S Tevethia
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.